Chemopreventive effect of a novel oleanane triterpenoid in a chemically induced rodent model of breast cancer

International Journal of Cancer

Volumn 133, Issue 5, 2013, Pages 1054-1063

  Bishayee, Anupam ^a   Mandal, Animesh ^b   Thoppil, Roslin J ^b   Darvesh, Altaf S ^b   Bhatia, Deepak ^b  

^a American University of Health Sciences   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

apoptosis; breast cancer; cell proliferation; chemoprevention; DMBA; oleanane triterpenoid

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; DIMETHYLBENZ[A]ANTHRACENE; METHYL 25 HYDROXY 3 OXOOLEAN 12 EN 28 OATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; TRITERPENOID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INHIBITION; CANCER PREVENTION; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RODENT; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BREAST CANCER; CELL PROLIFERATION; CHEMOPREVENTION; DMBA; OLEANANE TRITERPENOID;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; OLEANOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84879247591     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28108     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Henderson BE, Feigelson HS,. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427-33.
3. Lamartiniere CA,. Timing of exposure and mammary cancer risk. J Mammary Gland Biol Neoplasia 2002; 7: 67-76.
4. Lillie SE, Brewer NT, O'Neill SC, et al. Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy. Cancer Epidemiol Biomarkers Prev 2007; 16: 249-55.
5. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 2006; 12: 3661-97.
6. Jordan VC,. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007; 7: 46-53.
7. Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 2011; 12: 496-503.
8. Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W, et al. Chemoprevention of breast cancer. Cancer Treat Rev 2012; 38: 329-39.
9. Uray IP, Brown PH,. Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res 2011; 188: 147-62.
10. Reuben SC, Gopalan A, Petit DM, et al. Modulation of angiogenesis by dietary phytoconstituents in the prevention and intervention of breast cancer. Mol Nutr Food Res 2012; 56: 14-29.
11. Vadodkar AS, Suman S, Lakshmanaswamy R, et al. Chemoprevention of breast cancer by dietary compounds. Anticancer Agents Med Chem, 2012; 12: 1185-202.
12. Kado K, Forsyth A, Patel PR, et al. Dietary supplements and natural products in breast cancer trials. Front Biosci 2012; 4: 546-67.
13. Rabi T, Bishayee A,. Terpenoids and breast cancer chemoprevention. Breast Cancer Res Treat 2009; 115: 223-39.
14. Bishayee A, Ahmed S, Brankov N, et al. Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci 2011; 16: 980-96.
15. Ramachandran C, Rabi T, Fonseca HB, et al. Novel plant triterpenoid drug amooranin overcomes multidrug resistance in human leukemia and colon carcinoma cell lines. Int J Cancer 2003; 105: 784-9.
16. Rabi T, Karunagaram D, Nair MK, et al. Cytotoxic activity of amooranin and its derivatives. Phytother Res 2002; 16: S84-6.
17. Rabi T, Ramachandran C, Fonseca HB, et al. Novel drug amooranin induces apoptosis through caspase activity in human breast carcinoma cell lines. Breast Cancer Res Treat 2003; 80: 321-30.
18. Rabi T, Wang L, Banerjee S,. Novel triterpenoid 25-hydroxy-3-oxoolean-12- en-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Breast Cancer Res Treat 2007; 101: 27-36.
19. Ramachandran C, Nair PK, Alamo A, et al. Anticancer effects of amooranin in human colon carcinoma cell line in vitro and in nude mice xenografts. Int J Cancer 2006; 119: 2443-54.
20. Rabi T,. Antitumor activity of amooranin from Amoora rohituka stem bark. Curr Sci 1996; 70: 80-1.
21. Rabi T, Banerjee S,. Novel synthetic triterpenoid methyl 25-hydroxy-3-oxoolean-12-en-28-oate induces apoptosis through JNK and p38 MAPK pathways in human breast adenocarcinoma MCF-7 cells. Mol Carcinog 2008; 47: 415-23.
22. Rabi T, Banerjee S,. Novel semisynthetic triterpenoid AMR-Me inhibits telomerase activity in human leukemic CEM cells and exhibits in vivo antitumor activity against Dalton's lymphoma ascites tumor. Cancer Lett 2009; 278: 156-63.
23. Bishayee A, Martirosian A, Yeranosyan A,. Amooranin compounds and analogs thereof, and related methods of use. US Provisional Patent Application No. 61/580, 449, 2011.
24. Witty JP, Cempka T, Coffe RJ Jr, et al. Decreases tumor formation in 7,12-dimethylbenz(a)anthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cells apoptosis. Cancer Res 1995; 55: 1401-6.
25. Costa I, Solanas M, Escrich E,. Histopathological characterization of mammary neoplastic lesions induced with 7,12-dimethylbenz(a)anthracene in the rat: a comparative analysis with human breast tumors. Arch Pathol Lab Med 2002; 126: 915-27.
26. Bishayee A, Oinam S, Basu M, et al. Vanadium chemoprevention of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinogenesis: probable involvement of representative hepatic phase I and II xenobiotic metabolizing enzymes. Breast Cancer Res Treat 2000; 63: 133-45.
27. Morris TH,. Dose estimation among species. In:, Hawk CT, Leary SL, eds. Formulary for laboratory animals. Ames: Iowa State University Press, 1999. 3-14.
28. Bishayee A, Dhir N,. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact 2009; 179: 131-44.
29. Tsuchiya Y, Nakajima M, Yokoi T,. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005; 227: 115-24.
30. Jordan VC, Morrow M,. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 1999; 20: 253-78.
31. Brown NM, Belles CA, Lindley SL, et al. The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis 2010; 31: 886-93.
32. Hamdy SM, Latif AK, Drees EA, et al. Prevention of rat breast cancer by genistein and selenium. Toxicol Ind Health 2012; 28: 746-57.
33. Russo J, Gusterson BA, Rogers AE, et al. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990; 62: 244-78.
34. Farber E,. Clonal adaptation carcinogenesis. Biochem Pharmacol 1990; 39: 1837-46.
35. Waitzberg DL, Gonçalves EL, Faintuch J, et al. Effect of diets with different protein levels on the growth of Walker 256 carcinosarcoma in rats. Braz J Med Biol Res 1989; 22: 447-55.
36. Pollack M,. Do cancer cells care if their host is hungry? Cell Metab 2009; 9: 401-3.
37. Macrae FA,. Fat and calories in colon and breast cancer: from animal studies to controlled clinical trials. Prev Med 1993; 22: 750-66.
38. Rogozina OP, Bonorden MJ, Grande JP, et al. Serum insulin-like growth factor-I and mammary tumor development in ad libitum-fed, chronic calorie-restricted, and intermittent calorie-restricted MMTV-TGF-alpha mice. Cancer Prev Res 2009; 2: 712-9.
39. Christov K, Grubbs C, Shikaitis A, et al. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 2007; 13: 5488-96.
40. Leonardi E, Girlando S, Serio G, et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992; 45: 416-9.
41. Al-Dhaheri WS, Hassouna I, Al-Salam S, et al. Characterization of breast cancer progression in the rat. Ann N Y Acad Sci 2008; 1138: 121-31.
42. Hockenbery D, Nunez G, Milliman C,. Bcl2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
43. Brunelle JK, Letai A,. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009; 122: 437-41.
44. Chen M, Wang J,. Initiator caspases in apoptosis signaling pathways. Apoptosis 2002; 7: 313-9.
45. Place AE, Suh N, Williams CR, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003; 9: 2798-806.
46. Lapillonne H, Konopleva M, Tsao T, et al. Activation of peroxisome proliferator-activated receptor γ by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003; 63: 5926-39.
47. Konopleva M, Zhang W, Shi YX, et al. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2006; 5: 317-28.
48. Ling X, Konopleva M, Zeng Z, et al. The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res 2007; 67: 4210-8.
49. Liby K, Risingsong R, Royce DB, et al. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268. Clin Cancer Res 2008; 14: 4556-63.
50. Kim EH, Deng C, Sporn MB, et al. CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prev Res 2012; 5: 89-97.